We found that the hypoxia pathway played a key role in mutant KRAS-induced tumours and a small molecule, echinomycin, can effectively inhibit tumour growth, which indicates that the hypoxia pathway can be a therapeutic target and echinomycin is a good candidate for the treatment of cancer patients with KRAS mutation. The gene discussed is KRAS; the disease is neoplasm.